---
document_datetime: 2025-12-18 10:03:20
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/leflunomide-ratiopharm-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: leflunomide-ratiopharm-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5480023
conversion_datetime: 2025-12-28 17:26:04.309095
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Leflunomide ratiopharm

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 18/12/2025                          |                                             | SmPC and PL                      | To update Sections 4.4 and 4.8 of the SmPC and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000317185                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Sections 4.4 and 4.8 of the SmPC and Section 4 of the PL to implement the signal recommendations on pulmonary nodule (EPITT no 20155) following assessment of the same change for the reference product Arava. In addition, the MAH took the opportunity to implement editorial changes to (1) update the details of the local representatives for MT and ES, (2) delete the local representative for UK(NI) in line with the Windsor Framework and QRD template, and (3) update the PI in CS, SL and SV to align with the reference product   |            |     | Section 4 of the PL to implement the signal recommendations on pulmonary nodule (EPITT no 20155) following assessment of the same change for the reference product Arava.                                      |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000247176 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (IB) - To provide a revised RMP version to align the list of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/03/2025 | N/A | To provide a revised RMP version to align the list of safety concerns with the reference product. Furthermore, the Marketing Authorisation Holder has taken the opportunity to update the ATC code to L04AK01. |

<div style=\"page-break-after: always\"></div>

| with the reference product. Furthermore, the Marketing Authorisation Holder has taken the opportunity to update the ATC code to L04AK01.   |
|--------------------------------------------------------------------------------------------------------------------------------------------|